Filing identity and reporting period
Important: The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter ended September 30, 2013—not a filing by Madrigal Pharmaceuticals, Inc. The summary below reflects Synta’s filing.
Synta is a clinical-stage biopharmaceutical company developing internally discovered drug candidates, principally for cancer and inflammatory diseases. It reported no product revenue and retained full ownership of its candidates.
Financial performance and position
| Metric | Q3 2013 / September 30, 2013 | Comparison |
|---|---|---|
| Revenue | $0 | $0 in Q3 2012; nine-month revenue was $0 in 2013 versus $147,000 in 2012 |
| Research and development expense | $17.6 million for Q3; $51.9 million for nine months | Up 50% and 48%, respectively, from 2012 |
| General and administrative expense | $4.2 million for Q3; $12.2 million for nine months | Up 50% and 47%, respectively |
| Net loss | $22.5 million for Q3; $66.0 million for nine months | Q3 2012: $15.0 million loss; nine-month 2012: $44.7 million loss |
| Loss per share | $0.33 for Q3; $0.96 for nine months | 2012: $0.25 and $0.77, respectively |
| Operating cash used | $58.7 million for nine months | $41.6 million in the comparable 2012 period |
| Cash, cash equivalents and marketable securities | $53.4 million | $100.6 million at December 31, 2012 |
| Debt | $23.5 million scheduled principal outstanding; $7.4 million current and $16.1 million long term on the balance sheet | Debt increased following 2013 borrowing |
| Working capital | $28.8 million | $37.0 million in the comparable 2012 cash-flow discussion |
Gross margins are not applicable because the company reported no product sales. Total assets were $56.7 million and stockholders’ equity was $14.6 million at September 30, 2013. Nine-month financing activities provided $12.2 million; investing activities used $9.5 million. No material realized or other-than-temporary impairment losses on marketable securities were reported.
Material changes and business developments
- Losses widened as R&D spending rose, largely from GALAXY-2 Phase 3 start-up and enrollment, clinical pharmacology work, drug supply and related activities. G&A also increased, including personnel, stock compensation and professional fees.
- Ganetespib represented $47.1 million of nine-month R&D expense, up $15.4 million year over year. Investment in the early-stage portfolio increased, principally for the newly launched Hsp90-inhibitor drug-conjugate (HDC) platform; CRACM spending declined.
- The company obtained approximately $13.5 million of additional term-loan funding in 2013. GECC debt bears 9.75% interest, with interest-only payments through December 2013 and scheduled principal-and-interest payments beginning January 2014. Oxford debt bears 13.35% interest.
- GALAXY-1 interim results showed a reported signal in the prespecified chemosensitive NSCLC group (N=178): median overall survival of 10.7 months with ganetespib plus docetaxel versus 7.4 months with docetaxel; median progression-free survival was 5.3 versus 3.4 months. No benefit was observed in the refractory group. These were interim trial findings, not confirmatory Phase 3 results.
- GALAXY-2 was enrolling, with its population focused on chemosensitive patients. Management was considering increasing enrollment from approximately 500 to as many as 700; assuming that increase, interim analyses were expected in the second half of 2014 and final analysis in the first half of 2015.
- ENCHANT-1 met its criteria to advance to its second stage. Synta also expanded the study to include an ER/PR-positive breast cancer cohort and permitted evaluation of ganetespib with paclitaxel after monotherapy.
- Synta announced the HDC platform in September 2013 and reported more than 400 compounds synthesized, with preclinical proof-of-concept described in the filing. This remains an early-stage program.
Outlook, liquidity and risks
Management expected R&D costs, principally for ganetespib, to continue increasing through the remainder of 2013 and in 2014; G&A was also expected to rise. The company anticipated significant operating losses and no product revenue in the foreseeable future. Based on then-current activity assumptions, management said available cash resources were expected to fund operations into the second quarter of 2014.
Synta was pursuing preliminary partnership discussions and identified potential funding sources including collaborations, equity offerings, debt and its $28 million at-the-market sales agreement; no shares had been sold under that agreement by September 30, 2013. The filing warned that additional financing might not be available on acceptable terms and could dilute shareholders or require surrendering rights. Without adequate funding, programs could be delayed, modified or terminated. Development, clinical-trial, regulatory, safety, efficacy and commercialization outcomes remain uncertain.
Ganetespib plus docetaxel had higher reported rates of diarrhea, fatigue, febrile neutropenia and anemia than docetaxel alone in GALAXY-1; the filing described the overall safety profile as generally similar. There were no material changes to the prior annual-report risk factors, no material legal proceedings, and management reported disclosure controls were effective with no material quarter-specific changes to internal control over financial reporting.
Investor verification priorities
- Confirm the issuer: this is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Assess the cash runway against the company’s stated second-quarter 2014 funding estimate and its rising operating cash use.
- Verify the status, enrollment size and subsequent outcomes of GALAXY-2, and distinguish interim GALAXY-1 subgroup findings from confirmatory evidence.
- Review debt repayment obligations beginning in January 2014, interest costs, covenants and the $788,000 GECC exit fee.
- Check whether Synta secured partnerships or additional financing, and whether such financing altered dilution or program priorities.